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Background
Pancreatic cancer is the third leading cause of cancer death in both men and woman in
the USA and its incidence is progressively rising. Understanding the molecular
underpinnings of this lethal disease is crucial for developing potent therapies and
effective biomarkers. Studies have shown that pancreatic cancer is initiated as noninvasive ductal lesions that then progress to infiltrating pancreatic adenocarcinoma
through the accumulation of genetic alterations. Figure 1 shows the multistep
progression of pancreatic cancer from normal duct to infiltrating cancer. This
progression occurs through a series of histologically defined precursors called
Pancreatic Intraepithelial Neoplasia (PanIN). They are precursors to pancreatic cancer,
which is also known as pancreatic ductal adenocarcinoma (PDAC). In addition to
genetic alterations, recent studies have shown how epigenetic modifications play an
important role in cancer progression as well. Unlike genetic modifications,
epigenetics do not involve changes in DNA sequence, but rather affects gene
expression through reversible DNA or chromatin modifications, such as DNA
methylation and histone acetylation. Epigenetic regulation takes place through a
variety of different enzymes also known as the writers, readers, and erasers (Figure 2).
The writers add a variety of chemical groups onto DNA or histone amino acids, for
example histone lysine methylases can add up to three methyl groups onto one lysine.
One of the well characterized lysine modifications is H3K9me3, a mark for closed
chromatin (heterochromatin), which means it is inaccessible for gene expression i.e.
gene expression is suppressed. The modifications that writers lay are not permanent,
and can be reversed by another group of epigenetic modifiers known as erasers. Lysine
demethylases like KDM4C remove methyl groups from methylated lysines, resulting
in open chromatin formation (euchromatin) and allowing gene expression to occur. An
example is the histone demethylase KDM4C, an eraser in the Jumonji (JMJ) family.
The Structure of KDM4C is shown in Figure 3, and it consists of two JMJ family
domains, one of which is responsible for the structural integrity and the second, which
is the catalytic domain. Recent studies suggest that the altered regulation of these
epigenetic tools plays a key role in tumorigenesis. Since these modifications are
reversible and induced by deregulated enzymes, therapeutic approaches targeting these
alterations are areas of great interest in preclinical therapeutics. KDM4C
overexpression has been reported in lung, prostate, breast and brain cancers. KDM4C
has not been previously studied in pancreatic cancer. Therefore, we interrogated the
expression of KDM4C in pancreatic cancer and its effect on tumor growth.

Methods
In our laboratory we use orthogonal in-vitro and in-vivo model systems to study KDM4C
in PDAC. The in-vitro models are (i) human and mouse tissues for assessment of KDM4C
expression, and (ii) human pancreatic cancer cell lines with CRISPR/Cas9 induced
knockout of endogenous KDM4C. For in-vivo analyses, we have athymic mice that are
injected with PDAC cells bearing knockout of KDM4C versus control lines, as well as
novel genetically engineered mouse models of PDAC with deregulated Kdm4c expression.
Only the in vitro studies are described here, which were conducted by L.B. We first
sectioned human and mouse tissues and used multiplex IF technology to stain for KDM4C
expression, including the epithelial marker EpCAM and neoplastic marker CK19 in the
multiplex panel. Confocal microscopy was used to evaluate expression and
photomicrographs obtained. We then used CRISPR/Cas9 and guide RNAs against KDM4C
to knockout the endogenous protein in AsPC1 pancreatic cancer cell line. We conducted
real time PCR and western blot analysis for quantitative assessment of KDM4C
expression. Finally colony formation assays were conducted to evaluate the impact of
KDM4C loss on AsPC1 anchorage independent growth.

Results
KDM4C is Overexpressed in Pancreatic Cancer Tissues Compared to
Non-neoplastic Mouse and Human Pancreas

KDM4C Protein Levels Are Depleted After CRISPR Knockouts

Figure 5. Western Blot showing low tp absent Kdm4c protein levels in single cell clones of
AsPC1 cell line with CRISPR-induced KDM4C knockout, versus parental AsPC1 line.
Actin is used as a loading control.
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Figure 6. qRT-PCR shows depleted
levels of Kdm4c transcripts in the three
AsPC1 knockouts vs control cell line.

Loss of KDM4C Reduces Anchorage Independent Growth

Figure 1. Multistep progression model of pancreatic cancer

Figure 4. Multiplex immunofluorescence of normal pancreas (A-D) and pancreatic
ductal adenocarcinoma (I-L) showing overexpression of Kdm4C protein (red) in a
Kras;p53 mouse model of pancreatic cancer. EpCam (green), an epithelial marker
and CK19 (magenta), a marker of PDAC are also overexpressed. E-H, shows
elevated expression of Kdm4C in regions of acinar ductal metaplasia (ADM)
compared to histologically normal pancreas.

Figure 8. Colony Formation Assay. Well A is AsPC1 control cell line. Wells BB,C, and D
are the CRISPR knockouts KO1, KO2, and KO3 respectively.

Conclusions
KDM4C is overexpressed in human and mouse pancreatic cancer tissues relative to normal
pancreatic tissue. The downregulation of KDM4C expression significantly impedes
anchorage independent growth of AsPC1 cells. These foundational data form the basis for
future studies that will examine the downstream effector pathways of aberrant KDM4C
expression in pancreatic cancer, including transcripts whose expression is altered as a result
of changes in the H3K9me levels in the corresponding regulatory regions. We anticipate
these future studies will also identify potential actionable pathways that might form the basis
for reversing the oncogenic effects of KDM4C in pancreatic cancer.

Figure 2. Epigenetic modifiers - writers, readers and erasers
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Figure 3. KDM4C structure and domains

Figure 5. Immunofluorescence of Kdm4C (red), EpCam (green) and Ck19
(magenta) expression in resected normal (A-D) and cancer-bearing regions (E-L)
of a representative patient-derived pancreatic cancer sample. Note the elevated
expression of Kdm4C 9 in the PDAC region compared to the normal pancreas of
the same patient. Localization of Kdm4c protein within the neoplastic epithelium
is confirmed by co-localization of EpCAM and CK19 expression.
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